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A B S T R A C T
Purpose: The purpose of this study was to analyze national survey data to provide estimates of
prevalence of epilepsy and associated developmental disabilities and comorbid conditions.
Methods: We analyzed data from Cycle 3 of Canada’s National Longitudinal Survey of Children and
Youth. The NLSCY captured, socio-demographic information, as well as age, sex, education, ethnicity,
household income, chronic health related conditions from birth to 15 years old. The main survey
question intended to identify ‘‘epilepsy’’, ‘‘cerebral palsy’’, ‘‘intellectual disability’’, ‘‘learning disability’’,
and ‘‘emotional and nervous difﬁculties’’ in the population of children surveyed. Prevalence was based
on the national cross-sectional sample and used 1000 bootstrap weights to account for survey design
factors.
Results: Cycle 3 of the NLSCY had the largest number of patients with diagnosed epilepsy. Prevalence
ﬁgures (n/1000) for epilepsy and cerebral palsy (EPI_CP), epilepsy and intellectual disability (EPI_ID),
epilepsy and learning disability (EPI_LD), and epilepsy and emotional nervous difﬁculties (EPI_EMO_-
NERV) were 1.1, 1.17, 2.58 and 1.34 respectively. Amongst children with epilepsy, 43.17% reported the
presence of one or more of the above comorbid conditions.
Conclusion: These results provide an initial prevalence estimate of comorbid conditions with epilepsy in
Canadian children. In a high proportion of children with epilepsy, the PMK had reported at least one
comorbid disorder. These ﬁndings carry implications for health care utilization and long-term outcomes.
We discuss methodological aspects related to the ascertainment of epilepsy in both surveys, and to the
validity and implications of our ﬁndings.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epidemiological studies of chronic conditions are useful in
determining the distribution and impact of such diseases on child
health. Childhood epilepsy is a heterogeneous collection of
neurological conditions where epileptic seizures are recurrent,
unprovoked and paroxysmal in occurrence. Epilepsy can be the
consequence of heritable conditions (genetic) and secondary to a
coexistent neurological insult to the brain that is acute or remote in
origin. Incidence and prevalence are the most frequently used
measures of disease frequency.* Corresponding author at: Children’s Hospital, London Health Sciences Centre
B-174, 800 Commissioners Road East, N6A 5W9 Canada. Tel.: +1 519 685 8500x52177.
E-mail address: narayan.prasad@lhsc.on.ca (A.N. Prasad).
http://dx.doi.org/10.1016/j.seizure.2014.07.012
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights rePrevalence rates measure the existing number of cases in the
population (old and new cases) at a particular point in time (Point
prevalence) or over a deﬁned time period (Period prevalence).
Prevalence rates estimated through different studies vary depend-
ing on how cases are included (‘‘active cases’’ only vs ‘‘active and
inactive’’ and whether cases included single seizures, febrile
seizures, and acute symptomatic seizures). Children with epilepsy
frequently carry comorbid conditions like cerebral palsy, mental
retardation and learning disabilities.1 Prevalence data on epilepsy
vary by geographic region and ethnic group, as well as differ in
terms of methods of case ascertainment as well as time trends that
reﬂect changes with age.2 Population-based studies on prevalence
of epilepsy and comorbid conditions are listed among the priorities
for the public health dimension of epilepsy in the recent report
issued by the Institute of Medicine (IOM).3
We previously determined prevalence of epilepsy in Canadian
children using Cycles 2 and 3 of National Longitudinal Survey ofserved.
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comparable to other published studies.4 In the present study, we
extend the analysis to focus on the comorbid conditions associated
with epilepsy in children; namely cerebral palsy, mental handicap
(intellectual disability), learning disability, emotional and nervous
difﬁculties using data from Cycle 3 which had the largest number
of children diagnosed with epilepsy. The results will allow a
comparison with population-based studies of prevalence of
epilepsy and comorbidities in other countries.
2. Methods
2.1. About the NLSCY survey
The National Longitudinal Survey of Children and Youth
(NLSCY) was designed to study long-term trends in the physical
well being and social development of Canadian children from birth
to adulthood under the auspices of Social Program Information and
Analysis Directorate, Strategic Policy, Human Resources Develop-
ment Canada and the Special Surveys Division, Statistics Canada.5
The study started in 1994 with an initial cohort of children aged
0–11 years, and repeated every 2 years (1994/95, 1996/97, 1998/
99, and 2000/2001).
2.2. Sample size
Statistics Canada’s Labor Force Survey sample frame was used
to select a reliable random sample of the Canadian population in
Cycle 1 and a new cohort of 0–2 year olds was added in each new
cycle. The sample was intended to be longitudinal and cross-
sectional for Cycles 1–4 but this study only used the cross-sectional
design. The population sampling frame includes children and
youth in Canada’s 10 provinces but excludes respondents from the
north, persons residing in institutions or children with parents
serving in the military.
The population sample sizes were sufﬁciently large enough to
produce reliable estimates of these neurological conditions in the
Canadian population; however, the sample estimates may vary
somewhat from cycle to cycle. Some variation in the sample
estimates are expected and can be due to factors such as natural
variations in cycle composition, attrition, changes in the age of
individuals in the sample, missing data, some questions such as the
presence of a learning disability, intellectual disability restricted to
children older than 6 years, changes due to the inclusion of a new
cohort of 0–2 year olds in subsequent cycles, and changes in the
diagnosis of epilepsy as children age from cycle to cycle. For the
purpose of this study, we analyzed data from Cycle 3 that had the
largest number of respondents with a total of 31,963 children.
2.3. Measures
In keeping with the NLSCY’s survey format the person in the
household who was most knowledgeable (PMK) about the child (in
most cases the mother) responded to the following questions
(HLTQ45A and HLTQ51C in the survey)5:
‘‘Does the child have any of the following long-term conditions
that have been diagnosed by a health professional? . . . Epilepsy?,
Cerebral Palsy, Mental Handicap, Learning disability, Emotional,
Psychological or nervous difﬁculties . . ..’’ Long-term conditions
refer to conditions lasting 6 months or longer.
‘‘Does the child take any of the following prescribed medication
on a regular basis: Anti-convulsants or anti-epileptic pills?’’ (AED).
For comorbid estimates, respondents who reported both
epilepsy and the comorbid conditions were assigned a value of
1 and those who did not indicate both conditions were assigned a
value of 0.3. Analysis
Descriptive statistics were generated for Cycle 3 respondents
including the number reporting the comorbid condition, the
prevalence per 1000 in the population and the estimated number
of children and youth affected in Canada. The ﬁnal estimate was
conducted by applying cross-sectional weights, calculated for each
cycle by Statistics Canada. Statistical analysis of the dataset was
done using IBM1SPSS1 v22 for Windows1.
Relative risk ratios indicate increased or decreased risk of
having the condition for males compared to females. In addition,
relative risk estimates for each of the comorbidities of epilepsy (CP,
MR, LD, EMONERV) were obtained for the epilepsy group in
comparison to the group of children without reported epilepsy. In a
cross-sectional analysis of this nature both odds ratios and relative
risks can be used. Relative risk calculations are considered to be
more accurate, while odds ratios tend to overinﬂate the risk
estimates. In this context relative risk calculations are considered
to be more appropriate. For a discussion on the differences
between odds ratios and relative risk the reader may consult the
provided reference.6,7 Relative risk calculations were done by
creating a two by two table using an online calculator MEDCALC
(URL: http://www.medcalc.org/calc/relative_risk.php).
3.1. Weights
Cross-sectional weights representing the cross-sectional sam-
ple were calculated by Statistics Canada, for each cycle. Statistics
Canada also provides 1000 bootstrap sample weights for simulat-
ing the bootstrap method.8 Both methods were used for producing
point estimates with no observed differences in the estimates.
Cross-sectional weights were used to produce population
estimates that were used to estimate the number of children
and youth in the population with epilepsy alone and epilepsy and
one of the four comorbidities.
3.2. Missing data
The overall response rate to questions in the survey pertinent to
demographics and gender was 100%. The response rate however
varied with different questions in the survey, as a result of which
response rates were not uniform for all the questions posed in the
survey. There were a total of 30,592 valid responses (95.7%) and
1371 missing responses (4.3%) in the dataset for the primary
question on epilepsy (HLTQ45A). There were no missing responses
to the question components addressing comorbid conditions
surveyed. In an effort to understand missing data patterns in the
Epilepsy variable we conducted a logistic regression where the
dependent variable was coded as missing (coded as 1) or not
missing (coded 0). This missing indicator variable was analyzed to
determine if there was systematic ‘‘missingness’’ in the epilepsy
variable.
We recoded the age categories into indicator variables where
children who were, for example, 5 years old would be coded as 1 in
the variable age-ﬁve and children of any other age would be coded
as 0. The age groups 0–2 were combined due to a low sample sizes
in some age groups. Similarly, children who were 16 years old at
the time of the survey were included in the 15 year old category for
the same reason.
The ﬁndings indicated a much lower number of missing
responses among the cohort of 6 years and younger in comparison
with the group that was 7 years and older. The ﬁndings also
indicate females are much approximately 25% more likely to have
missing data on the epilepsy variable when compared to males. We
believe that the missing data do not carry a major impact on the
results and conclusions drawn in this study. Our suspicion is that
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self-reporting mechanism of the survey. The expected dissipation
of symptoms in older children could lead to some confusion when
parents tried to answer the question ‘Does your child have
epilepsy?’
4. Results
There were a total of 31,963 children in the survey (Males 51.3%,
Females 48.7%). In Cycle 3, 161 children were identiﬁed as having
epilepsy diagnosed by a health professional. In terms of age
distribution, there were 11,190 children (birth to 5 years), 11,348
children (6–10 years) and 8054 children (10–15 years).
The prevalence of epilepsy in Cycle 3 (5.3/1000) children has
already been published in a prior study while the prevalence of
treated epilepsy was lower (3.82/1000) children. Not all children
reported diagnosed with epilepsy were being actively treated with
anticonvulsant/antiepileptic drugs. One can speculate as to
whether the higher prevalence rates in response to the question
HLTQ45A included those responses where the epilepsy was either
untreated, as well those whose epilepsy was in remission. The
survey data do not allow for the analysis of sub-groups and do not
permit us to answer the question on the use of AED’s for indications
other than epilepsy in the survey population.
The comorbid disorders associated with epilepsy in the cross-
sectional analysis were surveyed on the basis that the PMK had
answered in the afﬁrmative to both sections of the HLTQ45A that
referred to the particular chronic conditions in the answers. In
Cycle 3 the prevalence ﬁgures (n/1000) epilepsy and cerebral palsy
(EPI_CP), epilepsy and intellectual disability (EPI_ID), epilepsy and
learning disability (EPI_LD), and epilepsy and emotional nervous
difﬁculties (EPI_EMO_NERV) were 1.1, 1.12, 2.58 and 1.34
respectively (Table 1). In the same cycle we surveyed, the relative
proportion of children with epilepsy alone accounted for 56.87%,Table 1
Prevalence of epilepsy and comorbid disorders in Canadian children – cross-sectional 
Total valid
responses
Yes 
Epilepsy prevalence self reported 30,592a 161 
Epilepsy prevalence (treated epilepsy) 31,963 122 
Epilepsy and cerebral palsy 31,963 36 
Epilepsy and intellectual disability 31,963 38 
Epilepsy and learning disability 19,402b 50 
Epilepsy and emotional and nervous symptoms 19,402b 26 
a There were 1371 missing responses for HLTQ45 from a total number of children 3
b The denominator is smaller as these two questions were deemed to be not applica
Table 2
Gender differences in children with epilepsy and comorbid conditions in Cycle 3 of NL
Condition Total Male Fem
Epilepsy + 161 102 
Epilepsy  30,431 15,656 14
Epilepsy + and CP + 36 20 
Epilepsy  and CP  31,927 16,370 15
Epilepsy + and intellectual disability + 37 18 
Epilepsy  and intellectual disability  31,925 16,371 15
Epilepsy + and learning disability + 49a 17 
Epilepsy  and learning disability  31,914 16,373 15
Epilepsy and emotional/nervous symptoms 
+ sign indicates that there was a ‘‘yes’’ response to the relevant survey question on the 
a In one case the value of the weight variable was zero, negative, or missing. Such case
cases, and hence a discrepancy of n of 1 in the total number of males and females in each 
survey.
b Low cell counts in this category; Statistics Canada conﬁdentiality rules do not perwhile 10.03% reported at least one comorbid condition, 23.57% had
at least two comorbid conditions while 9.53% had three or more
conditions.
In a further analysis of the Cycle 3 data the role of gender
differences in the likelihood of having epilepsy and associated
conditions was examined by calculating the relative risk (Table 2).
Statistically signiﬁcant relative risks (p < 0.05) indicate that male
children in the survey were more likely to have epilepsy without
any associated comorbidity (1.63, 95% CI 1.18–2.24, p = 0.003).
Further, male children with epilepsy were less likely to carry an
associated learning disability (0.502, 95% CI 0.28–0.902, p = 0.025)
in comparison to females with epilepsy in the survey population.
There were no statistically signiﬁcant differences between male
and female children with respect to epilepsy associated with
cerebral palsy and intellectual disability (Table 2).
Finally, relative risk and conﬁdence intervals for comorbidities
in children with epilepsy and without epilepsy was signiﬁcant
(p < 0.001) revealing a greater risk for the epilepsy group. When
the comorbid condition is itself treated as an independent variable
the risk of epilepsy remains high (Table 3). The relative risk of
cerebral palsy was (RR 136.08, 95% CI 91.27–202.90) and for
intellectual disability/mental handicap was (RR 65.08, 95% CI
46.53–91.04) in children with epilepsy based on survey data.
5. Discussion
The NLSCY survey provides useful and valid estimates of the
prevalence of epilepsy and use of AEDs in Canadian children birth
to 15 years. In a previous study using the NLSCY data, robust
estimates of prevalence ﬁgures were obtained in Cycles 2 and 3 (2:
1996–1997, 3: 1998–1999).4 The prevalence rates estimated by
the present survey in Canadian children from birth to 15 years is
5.3/1000, corresponding to a population-based estimate of 32,045
affected children in the Canadian population. These results areanalysis (NLSCY data) from Cycle 3.
No Prevalence/
1000
Estimated number of affected children
in Canada (Census data)
30,431 5.3 32,045
31,841 3.82 18,952
31,927 1.1 6949
30,925 1.17 7581
19,352 2.58 10,107
19,376 1.34 5243
1,963 in Cycle 3 of the NLSCY.
ble to the children in the survey under the age of 6 years (12,564).
SCY.
ale Relative
risk (male)
95% Conﬁdence
intervals
p value
(signiﬁcant  0.05)
59 1.63 1.18–2.24 0.003
,775
16 1.19 0.62–2.29 0.61
,557
19 0.90 0.47–1.71 0.75
,554
32 0.502 0.28–0.902 0.025
,541
Suppressed due
to low n valuesb
epilepsy and/or comorbid condition, while the ‘‘’’ sign indicates a ‘‘no’’ response.
s are invisible to statistical procedures and graphs which need positively weighted
category in comparison to Table 1 which gave total n values for each category in the
mit release of this data.
Table 3
Relative risk analysis of epilepsy and comorbid conditions.
Variable + Variable  Relative risk (RR) 96% CI limits Z statistic p values
Epilepsy+ Epilepsy
CP+ 36 50 136.08 91.271–202.90 24.109 <0.0001
CP 125 30,380
CP+ CP
Epilepsy+ 36 125 102.1563 75.35–138.50 29.791 <0.0001
Epilepsy 50 30,380
Epilepsy+ Epilepsy
ID+ 38 109 65.08 46.53–91.04 24.38 <0.0001
ID 123 30,322
ID+ ID
Epilepsy+ 38 123 63.98 46.199–88.61 25.02 <0.0001
Epilepsy 109 30,322
Epilepsy+ Epilepsy
LD+ 50 1057 6.2823 4.98–7.92 15.533 <0.0001
LD 95 18,200
LD+ LD
Epilepsy+ 50 95 8.7 6.21–12.18 12.58 <0.0001
Epilepsy 1057 18,200
Epilepsy+ Epilepsy
Emonerv+ 26 394 8.76 6.10–12.60 11.8 <0.0001
Emonerv 119 18,863
Emonerv+ Emonerv
Epilepsy+ 26 119 9.87 6.53–14.92 10.86 <0.0001
Epilepsy 394 18,863
CP = cerebral palsy, ID = intellectual disability, LD = learning disability, Emonerv = emotional nervous symptoms, + sign indicates a Yes response in the survey,  sign indicates
a No response in the survey.
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cial surveys.9
Cycle 3 of the NLSCY had the largest number of respondent
cases of epilepsy. For this reason, we have limited our discussion of
prevalence of comorbid disorders to the respondents in this cycle.
Based on the answers to the question HLQT45A in the survey, we
were able to estimate the prevalence of four comorbid conditions
i.e. cerebral palsy, intellectual disability, learning disability, and
presence of emotional and nervous symptoms.
The most salient ﬁnding in this study was the high association
with comorbid developmental disabilities in children with
epilepsy. Forty three percent of the children had comorbid
conditions, as many as 33% had two or more conditions. Compared
to children not reported to have epilepsy, the relative risk of a
comorbid condition (CP, ID, LD, EMONERV) in the population of
children with epilepsy is statistically signiﬁcant. The risk is
particularly high for cerebral palsy dependent on epilepsy, as well
as for epilepsy dependent on cerebral palsy. This ﬁnding is
biologically plausible as a signiﬁcant proportion of childhood
epilepsy is either cryptogenic or symptomatic in etiology,
suggesting that epilepsy in these children is attributable to
abnormalities in the developing nervous system, a feature
common to cerebral palsy as well.10
In general, epilepsy prevalence estimates generated through this
analysis are similar to other population-based studies in the
developed world.11,12 However, these estimates are lower in
comparison to prevalence rates reported from Latin America, South
Asia and other developing nations.1,9,10The higher prevalence of head
injury, acute infections (meningitis and encephalitis), poor prenatal
and intrapartum care, chronic CNS infections like neurocysticercosis
and tuberculosis likely contribute to observed differences.13
In the Metropolitan Atlanta Developmental Disabilities study
multiple source case ascertainment was used to conﬁrm a
diagnosis of epilepsy, the lifetime prevalence of epilepsy was 6/
1000 (95% CI 5.5–6.5), and 35% reported an additional disability(MR, CP, LD, Visual or hearing impairment).14 Similarly in the study
reported from Turku, Finland an associated neurological deﬁcit
was reported in 39.9%, learning disabilities in 23.1%, mental
retardation in 31.4%.12 In a Swedish study a prevalence rate of 4.2/
1000 was reported, the associated comorbidity of mental
retardation was estimated to be 1.7/1000.11 In a recent study on
the proﬁle of epilepsy in children 0–17 years of age in the US, a
current prevalence rate was 6.3/1000 (95% CI 4.9–7.8) and a
lifetime prevalence of epilepsy/seizure disorder was 10.2/1000
(95% CI 8.7–11.8). The study reported an increasing prevalence of
epilepsy with age, a male preponderance as well as a larger number
of mental health and developmental comorbidities.10 Of particular
signiﬁcance is the occurrence of developmental delay (50%) and
learning disabilities (56%) in this survey population.
The association between learning disability, mental retardation,
and epilepsy has been documented in population-based studies. It
is estimated that 20–25% of people with moderate to severe
learning disabilities have epilepsy as a comorbid condition.12,15
A highly signiﬁcant association of epilepsy with cerebral palsy
has been noted in clinical studies. In one study, nearly half (47%) of
the patients diagnosed with spastic quadriplegic cerebral palsy,
also had epilepsy.16 Similarly in a 10 year follow up of epilepsy the
Dutch population-based study on cerebral palsy, epilepsy was a
comorbid condition in 21.3%, and active epilepsy in 18.9%.17
The ﬁnding of a statistically signiﬁcant male preponderance of
epilepsy in Canadian children has not been previously reported.
Similarly, the preponderance of learning disabilities in female
children with epilepsy, observed in this survey, is surprising since a
slight male preponderance has been suggested in other population
studies. Furthermore, in healthy children, reading disabilities are
reportedly more frequent in males. The issue of gender differences
in the prevalence rates for epilepsy has been considered in other
population studies and a slight male preponderance is generally
accepted.10,14 Gender differences in children with learning
disability without epilepsy are considered to be controversial, a
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to reading disability.18 Whether there are biological or multifac-
torial causes underlying gender differences and learning disabil-
ities still needs to explored.19
In conclusion, the ﬁndings of this national study provide valid
and reliable estimates of prevalence rates for epilepsy in Canadian
children, as well as for each of the four comorbid conditions
selected. In addition, the ﬁndings suggest that a signiﬁcant
proportion of children with epilepsy have associated comorbid
neurological impairment (cerebral palsy) and other developmental
disabilities. The associated comorbid condition may be under
diagnosed leaving these children at risk of academic under
achievement, and any remedial interventions that could be of
value may be delayed.
There are several limitations to this study as it utilizes survey
data to understand the epidemiology of epilepsy. However, the
estimates of epilepsy obtained in this analysis are remarkably close
to the Canadian data from previous Canadian surveys as well as
from those from other countries.9,12
Epilepsy is a dynamic condition; as children grow older new
cases can be diagnosed in some, while others may go into
remission. It is therefore difﬁcult to precisely capture the total
number of children who are impacted by epilepsy during
childhood in cross-sectional surveys of this nature. A longitudinal
study of the eight cycles of the NLSCY is planned, the results of
which may shed further light on the direction and trajectories of
epilepsy and comorbidities.
Another limitation that has to be considered is that the’ report
of epilepsy may be less reliable than measures diagnosed by a
physician. To avoid this problem the survey question speciﬁcally
asked if the condition had been chronic (lasting longer than 6
months) and had been diagnosed by a physician. Underreporting
could still occur as families may not have accepted the diagnosis of
epilepsy, or may have been given an alternate diagnosis such as
seizure disorder, or may have been prescribed AEDs for conditions
other than seizures (e.g. psychiatric diagnoses).
The NLSCY survey did not include questions about comorbid-
ities associated with epilepsy syndromes, seizure type and severity
of epilepsy. Therefore, we were unable to sub-classify epilepsy
diagnoses providing added clinical data relevant to this discussion.
Finally, there is lack of information about etiology as well as the
temporal contiguity of the onset of the comorbid condition (before
or after onset of epilepsy).
Notwithstanding these limitations, the NLSCY data proves to be
a useful resource in understanding the epidemiology and the social
determinants of epilepsy. Information in such studies should
always be considered in concert with each other rather than on
their own merit. The combined knowledge from both clinical and
population studies ﬁnd their strength when they ﬁnd agreement
on the issue and present opportunities for inquiry when they
disagree.Conﬂict of interest statement
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